Mantle cell lymphoma (MCL) is one of several sub-types of B-cell lymphomas. The malignancy is very aggressive and average survival time is short. The hallmark of MCL is over expression of cyclin D1, however about 15% of all MCL cases do not display this over expression and are easily misdiagnosed. Recently the transcription factor Sox11 has been shown to be specifically over expressed in the nucleus of MCL-tumour cells, and polyclonal rabbit anti-Sox11 antibodies have been used to successfully identify MCL in both cyclin D1 positive and negative cases. Howev-er, human recombinant MCL-specific antibodies as have several advantages over these polyclonal rabbit antibodies; they can easily be produced in large quantities in vitro, their specificity is constant from batch to batch and they can possibly be used for therapeutic purposes. Because of this, it is desirable to produce human recombinant antibodies against proteins over expressed in MCL. In this study human recombinant IgGs have been produced towards two pro-teins over expressed in MCL, Sox11 and KIAA0882. This was done by cloning of single chain variable fragments (scFvs), previously selected from a large scFv library through phage display selection against Sox11- and KIAA0882-protein epitope signature tag (PrEST), into vectors containing human IgG constant regions followed by expression of human IgG antibodies in human embryonic kidney (HEK) 293 cells. One IgG clone for each antigen was shown to be functional and specific. Both clones were shown to have overlapping binding epitopes with their polyclonal rabbit antibody counterpart (rabbit anti-Sox11/KIAA0882) through competitive ELISA. The anti-Sox11 IgG was able to detect two bands in cell lysate in Western blot, of which one probably is Sox11 while the other band possibly could be Sox4. However, this needs to be confirmed in future experiments. The affinity of the anti-Sox11 IgG was measured in Biacore and compared to the affinity of its original scFv. This gave a rough estimation of the affinities, but the values are unreliable and the measurements need to be redone. Although more work has to be put into evaluating the potential of the produced IgGs, they compose a promising starting point to an improved understanding and improved diagnosis of MCL.

<p>Mantle cell lymphoma (MCL) is one of several sub-types of B-cell lymphomas. The malignancy is very aggressive and average survival time is short. The hallmark of MCL is over expression of cyclin D1, however about 15% of all MCL cases do not display this over expression and are easily misdiagnosed. Recently the transcription factor Sox11 has been shown to be specifically over expressed in the nucleus of MCL-tumour cells, and polyclonal rabbit anti-Sox11 antibodies have been used to successfully identify MCL in both cyclin D1 positive and negative cases. Howev-er, human recombinant MCL-specific antibodies as have several advantages over these polyclonal rabbit antibodies; they can easily be produced in large quantities in vitro, their specificity is constant from batch to batch and they can possibly be used for therapeutic purposes. Because of this, it is desirable to produce human recombinant antibodies against proteins over expressed in MCL. In this study human recombinant IgGs have been produced towards two pro-teins over expressed in MCL, Sox11 and KIAA0882. This was done by cloning of single chain variable fragments (scFvs), previously selected from a large scFv library through phage display selection against Sox11- and KIAA0882-protein epitope signature tag (PrEST), into vectors containing human IgG constant regions followed by expression of human IgG antibodies in human embryonic kidney (HEK) 293 cells. One IgG clone for each antigen was shown to be functional and specific. Both clones were shown to have overlapping binding epitopes with their polyclonal rabbit antibody counterpart (rabbit anti-Sox11/KIAA0882) through competitive ELISA. The anti-Sox11 IgG was able to detect two bands in cell lysate in Western blot, of which one probably is Sox11 while the other band possibly could be Sox4. However, this needs to be confirmed in future experiments. The affinity of the anti-Sox11 IgG was measured in Biacore and compared to the affinity of its original scFv. This gave a rough estimation of the affinities, but the values are unreliable and the measurements need to be redone. Although more work has to be put into evaluating the potential of the produced IgGs, they compose a promising starting point to an improved understanding and improved diagnosis of MCL.</p>

Thesis (doctoral)--Lund University, 1998. / Added t.p. with thesis statement inserted. Includes bibliographical references.

Thesis (MSc (Veterinary Tropical Diseases, Veterinary Science))--University of Pretoria, 2008. / Includes bibliographical references. Also available in print format.

Thesis (MSc (Veterinary Tropical Diseases, Veterinary Science))--University of Pretoria, 2008. / Includes bibliographical references. Also available in print format.

Thesis (doctoral)--Lund University, 1998. / Added t.p. with thesis statement inserted. Includes bibliographical references.

O diagnóstico da infecção por ETEC é baseada na detecção dos seus principais fatores de virulência, as toxinas termo-lábil e termo-estável, através de métodos de biologia molecular ou imunossorológicos. A tecnologia de anticorpos recombinantes permite a obtenção de moléculas com baixo custo, afinidades e especificidades desejáveis, através da clonagem dos domínios variáveis das cadeias leve e pesada da imunoglobulina, fusionados a um ligante flexível que permite a correta interação entre os domínios e a preservação do sítio de ligação ao antígeno. Este estudo teve como objetivo a construção de um fragmento variável em cadeia única (scFv), a partir de hibridomas produtores de anticorpo monoclonal anti-LT, seguida da sua produção em células bacterianas. Um fragmento variável em cadeia única com 723 pb foi obtido, sendo expresso em cepa de Escherichia coli como uma proteína com peso molecular aparente de 30 kDa. Após purificação em cromatografia de afinidade a Ni2+ e renaturação, o scFvLT foi capaz de reconhecer a toxina LT por ELISA de captura e Immunodot, porém não foi capaz de reconhecer as subunidades da toxina LT, por Immunoblotting, nem de neutralizar sua atividade citopática em células adrenais Y1. / Heat-labile (LT) and heat-stable (ST) toxins are the main ETEC\'s virulence factors and infection diagnosis is based on their detection by molecular biology or immunoserological methods. The advances on antibody biotechnology provide alternatives to obtain low cost antibodies with desirable affinities and specificities by cloning immunoglobulin\'s heavy and light variable domains (HV and LV) as a single-chain fusion interspaced by a flexible linker, which allowing the correct interaction between the domains and preserving the antigen-binding site. In this study we aimed the construction of a scFv upon hybridoma cells that produce an anti-LT monoclonal antibody following its bacterial production. A single-chain fragment variable with 723 bp was obtained and expressed as a protein with apparent molecular weight of 30 kDa in Escherichia coli strain. The scFvLT recombinant antibody was submitted to metal affinity chromatography and refolding and was tested by immunoenzimatic assays. Refolded scFvLT was able to recognized LT toxin by capture ELISA and Immunodot. However, scFvLT wasnt able to recognize LT toxin subunits by Immunoblotting neither neutralize its activity in Y1 adrenal cells.

Made available in DSpace on 2014-06-11T19:27:23Z (GMT). No. of bitstreams: 0 Previous issue date: 2009-12-22Bitstream added on 2014-06-13T18:56:05Z : No. of bitstreams: 1 fernandes_cc_me_jabo.pdf: 1349174 bytes, checksum: b0d752648346a29041d0fbd5f330fbf6 (MD5) / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / Anticorpos monoclonais se constituem na base de vários testes usados na detecção e na identificação de antígenos. Nesse contexto, tais imuno-reagentes têm sido extensivamente empregados na identificação de estirpes virais envolvidas na etiologia de surtos de bronquite infecciosa a campo, permitindo o aperfeiçoamento das técnicas de detecção e caracterização antigênica do vírus da bronquite infecciosa das galinhas (VBI). No presente estudo, uma biblioteca de fragmentos de anticorpos de galinha originalmente preparada por “phage display” contra a estirpe vacinal (H120) do VBI, foi usada para a seleção de fragmentos de anticorpos recombinantes com reatividade cruzada para as estirpes heterólogas IBVPR01, IBVPR05, isoladas de surtos a campo no Brasil e SE-17, isolada nos Estados Unidos. Após três ciclos de “panning”, foi identificado pelo ELISA um conjunto de 15 anticorpos scFv expressos em fagos e com reatividade cruzada para essas mesmas estirpes do VBI. A análise por Western-blotting revelou que três desses clones apresentavam fagos expressando fragmentos de anticorpos monoclonais com reatividade cruzada para a nucleoproteína N das três estirpes do VBI e também para a forma recombinante dessa nucleoproteína derivada da estirpe M41. Concluindo, os fragmentos de anticorpos monoclonais recombinantes scFv-N produzido em fagos interagem com um epítopo mais conservado da proteína N do VBI e apresentam um grande potencial para utilização na detecção e no diagnóstico direto desse vírus e no estudo de evolução de variantes desse vírus. / Monoclonal antibodies are the basis of various techniques used for antigen detection or characterization, and their use is specially recommended for the identification of viral strains involved in the etiology of outbreaks of infectious bronchitis, because these antibodies are homogeneous, highly specific and fully characterized, allowing the improvement of detection of immunological techniques and antigenic characterization of avian infectious bronchitis virus strains (IBV). We used a phage display library prepared previously against the IBV vaccine strain (H120) for the selection of new scFv antibody fragments reacting with heterologous IBV strains isolated from outbreaks in Brazil (IBVPR01, IBVPR05) and USA (SE-17). After three cycles of panning a set of 15 scFv antibodies was expressed in phages and exhibited crossreaction in ELISA with these three viral strains. Western-blotting analysis showed that three of this clone set were expressing scFv specific for the nucleoprotein of these IBV strains, as well as to the recombinant form of this protein derived from M41 strain of IBV. In conclusion, the recombinant fragments of monoclonal antibodies expressed by phage-display technique have a great potential for future use in immunodiagnostic techniques and study the evolution of variant strains of this virus.

O diagnóstico da infecção por ETEC é baseada na detecção dos seus principais fatores de virulência, as toxinas termo-lábil e termo-estável, através de métodos de biologia molecular ou imunossorológicos. A tecnologia de anticorpos recombinantes permite a obtenção de moléculas com baixo custo, afinidades e especificidades desejáveis, através da clonagem dos domínios variáveis das cadeias leve e pesada da imunoglobulina, fusionados a um ligante flexível que permite a correta interação entre os domínios e a preservação do sítio de ligação ao antígeno. Este estudo teve como objetivo a construção de um fragmento variável em cadeia única (scFv), a partir de hibridomas produtores de anticorpo monoclonal anti-LT, seguida da sua produção em células bacterianas. Um fragmento variável em cadeia única com 723 pb foi obtido, sendo expresso em cepa de Escherichia coli como uma proteína com peso molecular aparente de 30 kDa. Após purificação em cromatografia de afinidade a Ni2+ e renaturação, o scFvLT foi capaz de reconhecer a toxina LT por ELISA de captura e Immunodot, porém não foi capaz de reconhecer as subunidades da toxina LT, por Immunoblotting, nem de neutralizar sua atividade citopática em células adrenais Y1. / Heat-labile (LT) and heat-stable (ST) toxins are the main ETEC\'s virulence factors and infection diagnosis is based on their detection by molecular biology or immunoserological methods. The advances on antibody biotechnology provide alternatives to obtain low cost antibodies with desirable affinities and specificities by cloning immunoglobulin\'s heavy and light variable domains (HV and LV) as a single-chain fusion interspaced by a flexible linker, which allowing the correct interaction between the domains and preserving the antigen-binding site. In this study we aimed the construction of a scFv upon hybridoma cells that produce an anti-LT monoclonal antibody following its bacterial production. A single-chain fragment variable with 723 bp was obtained and expressed as a protein with apparent molecular weight of 30 kDa in Escherichia coli strain. The scFvLT recombinant antibody was submitted to metal affinity chromatography and refolding and was tested by immunoenzimatic assays. Refolded scFvLT was able to recognized LT toxin by capture ELISA and Immunodot. However, scFvLT wasnt able to recognize LT toxin subunits by Immunoblotting neither neutralize its activity in Y1 adrenal cells.

Genetic engineering has allowed the design and production of recombinant antibodies (rmAbs) in plants. Nowadays, rmAbs are used in the treatment of a wide range of pathologies such as infectious diseases, inflammatory diseases and cancer, making rmAbs an important group of biomolecules within the pharmaceutical and biotechnology industry. By the time this study was started, the immunoglobulin G (IgG) was the antibody isotype predominantly expressed in plants. In recent years Modular DNA cloning technology has facilitated antibody engineering, with the development and expression of new rmAbs formats. However, there is hardly any study where different antibody formats are produced and compared in terms of yield and neutralizing capacity. Therefore, the starting point of the first chapter of this thesis is a comparative study where five different formats of the same commercial rmAb (Infliximab) against the human cytokine Tumor Necrosis Factor (TNF-¿) were expressed and compared. The results obtained in Chapter 1 demonstrate that both the isotype and the structure of the chosen rmAb influence the yield and the neutralizing capacity of rmAb. The expression of new antibody formats not only refers to the antibody isotype or structure; the format also refers to the combination of antibody idiotypes, leading to the production of oligo or polyclonal antibodies. Therefore, the possibility of co-expressing different monoclonal antibodies simultaneously in plants (creating oligoclonal or polyclonal formats) was raised. In the second chapter of this thesis, the expression of three rmAbs against the Ebola virus glycoprotein was studied. The three rmAbs were transiently expressed in N. benthamiana individually, by establishing separated production lines; in parallel, all three rmAbs were also co-expressed simultaneously in the same production line. The results obtained in this chapter demonstrated that the individual expression of rmAbs is feasible. However, when all three rmAbs are co-expressed, a drastic decrease in the binding of the antibody to the antigen was observed due to chain shuffling, as each heavy chain (HC) can be bound to any light chain (LC) other than its cognate chain, giving rise to an antibody cocktail with lower activity. With the objective of developing a method that allows co-expression of several rmAb in a single production line, we next proposed to exploit the viral interference phenomenon (also known as superinfection exclusion, SE). The results shown in Chapter three demonstrate that the production of an oligoclonal cocktail composed of 36 rmAbs in plants was possible using a viral expression system showing SE. The data obtained in this chapter showed that the resulting oligoclonal cocktail was active and capable of neutralizing toxic activities of the venom of the snake Bothrops asper in vitro and in vivo, wich was used as a model for studying the efficacy of the oligoclonal antibodies produced. The results of this thesis confirm and support the use of plants as platforms for the expression of alternative formats of antibodies. / La ingeniería genética ha permitido el diseño y la producción de anticuerpos recombinantes (rmAbs) en plantas. Hoy en día, los rmAbs se utilizan en el tratamiento de un amplio rango de patologías como enfermedades infecciosas, enfermedades inflamatorias y cáncer, convirtiéndose en un importante grupo de biomoléculas dentro de la industria farmacéutica y biotecnológica. Hasta la fecha de este estudio, en plantas se ha producido mayoritariamente la inmunoglobulina del tipo G (IgG). Gracias al desarrollo de la ingeniería del ADN recombinante y de la ingeniería de anticuerpos, es posible diseñar y producir nuevos formatos de rmAbs. Sin embargo, apenas existen estudios comparativos donde se demuestre si el formato de anticuerpo elegido es el idóneo en términos de rendimiento y capacidad neutralizante. Por tanto, el punto de partida del primer Capítulo de esta tesis consistió en la realización de un estudio comparativo de la expresión en plantas de cinco formatos distintos de un mismo rmAb comercial (Infliximab) frente a la citoquina humana Tumor Necrosis Factor (TNF-¿). Los resultados obtenidos en el Capítulo 1 demuestran que tanto el isotipo como la estructura del rmAb elegido influye en los niveles de rendimiento y en la capacidad neutralizante del rmAb. La expresión de nuevos formatos de anticuerpos no solo afecta al isotipo o a la estructura de las regiones constantes, sino que también se puede incluir en este término la expresión conjunta de distintos idiotipos de anticuerpos recombinantes, dando lugar a anticuerpos policlonales u oligoclonales recombinantes. Por tanto en esta tesis se planteó la posibilidad de co-expresar simultáneamente distintos anticuerpos monoclonales en plantas formando un cóctel oligoclonal. En el segundo Capítulo de esta tesis se diseñaron tres rmAbs frente a la glicoproteína de la cubierta del virus del Ébola. Los tres rmAbs se expresaron transitoriamente en N. benthamiana de manera individual mediante el establecimiento de líneas paralelas de producción y también se co-expresaron los tres rmAbs simultáneamente en una misma línea de producción. Los resultados obtenidos en este Capítulo demostraron que la expresión de los rmAbs de manera individual es factible. Sin embargo, cuando se co-expresan los tres rmAbs se observa una drástica disminución en la unión del anticuerpo al antígeno debido al barajado de cadenas, fenómeno por el cual cada cadena pesada (HC) se puede unir con cualquier cadena ligera (LC) distinta de su acompañante, dando lugar a un anticuerpo con una baja actividad. Finalmente, con el objetivo de desarrollar un método que permita co-expresar en una misma línea de producción varios rmAbs de forma reproducible se propuso explotar el fenómeno de la exclusión viral, un característica propia de los virus de plantas. Los resultados mostrados en el Capítulo 3 demuestran que es posible la producción de un cóctel oligoclonal compuesto por 36 rmAbs en N. benthamiana aprovechando el fenómeno de la exclusión viral. Los datos obtenidos en este capítulo muestran que el cóctel oligoclonal producido de esta forma mantiene intactas las actividades de los anticuerpos individuales y es capaz de neutralizar las actividades tóxicas del veneno de la serpiente Bothrops asper en ensayos in vitro e in vivo. Los resultados de esta tesis confirman y avalan el uso de las plantas como plataformas de expresión de formatos alternativos de anticuerpos. / El desenvolupament de l'enginyeria genètica ha permès el disseny i la producció d'anticossos recombinants (rmAbs) en plantes. Hui en dia, els rmAbs s'utilitzen en el tractament d'un ampli rang de patologies com malalties infeccioses, malalties inflamatòries i càncer convertint-se en un important grup de biomolècules dins de les indústries farmacèutiques i biotecnològiques. Fins a la data, s'han expressat majoritàriament la immunoglobulina del tipus G. Gràcies al desenvolupament de l'enginyeria de l'ADN recombinant i l'enginyeria dels anticossos s'han desenvolupat i expressat formats alternatius de rmAbs. Tanmateix, hi ha molts pocs estudis comparatius on es demostra si el format de l'anticòs elegit influeix en el rendiment i en la capacitat neutralitzant. Per tant, el punt de partida del primer Capítol d'esta Tesi és la realització d'un estudi comparatiu on s'expressen cinc formats diferents d'un mateix anticòs comercial (Infliximab) front a la citocina humana Tumor Necrosis Factor (TNF-¿). Els resultats obtesos demostren que tant l'isotip com l'estructura del rmAb elegit influeix en el rendiment i en la capacitat neutralitzant del rmAb. L'expressió de nous formats d'anticossos no sols afecta a l'isotip o a l'estructura del rmAb sinó que també pot incloure's dins d'aquest concepte l'expressió individual i l'expressió conjunta de diferents rmAbs. Partint d'aquesta hipòtesi, es va plantejar la possibilitat de co-expressar diferents rmAbs (còctel oligoclonal) en plantes. En el segon Capítol d'esta tesi es dissenyaren tres rmAbs front a la glicoproteïna del virus de l'Ébola. Els tres rmAbs s'expressaren transitòriament en N. benthamiana de manera individual mitjançant l'establiment de línies paral·leles de producció i també es co-expressaren els tres rmAbs en la mateixa línia de producció. Els resultats obtesos en este Capítol demostraren que l'expressió dels rmAbs de manera individual és factible. Tanmateix, quan es co-expressaren els tres rmAbs s'observà una dràstica disminució en la unió de l'anticòs a l'antigen com a conseqüència del shuffling chain, pel qual la cadena pesada (HC) s'uneix amb qualsevol cadena lleugera (LC) diferent a la seua acompanyant, formant un anticòs amb una baixa capacitat d'unió a l'antigen. Amb l'objectiu de desenvolupar un mètode que permeta co-expressar, en una mateixa línia de producció, un còctel oligoclonal es proposà explotar el fenomen de l'exclusió viral. Els resultats obtesos en el Capítol 3 demostren que l'expressió d' un còctel oligoclonal format per 36 rmAbs en plantes és possible. Els resultats mostren que el nostre còctel oligoclonal es capaç de neutralitzar activitats tòxiques del verí de la serp Bothrops asper en assaigs in vitro i in vivo. Els resultat obtesos en aquesta Tesi confirmen i avalen l'ús de les plantes com plataformes d'expressió de formats alternatius d'anticossos. / Huet Trujillo, E. (2017). Nuevas metodologías para la producción de anticuerpos recombinantes en plantas [Tesis doctoral no publicada]. Universitat Politècnica de València. https://doi.org/10.4995/Thesis/10251/90469 / TESIS